Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin and Dell Children's Medical Center, Austin, TX.
Department of Pediatrics, University of Texas at Austin Dell Medical School, Austin, TX.
Pediatr Crit Care Med. 2022 Dec 1;23(12):e583-e589. doi: 10.1097/PCC.0000000000003088. Epub 2022 Oct 5.
Currently, surgical repair of tetralogy of Fallot (TOF) is associated with an 1.1% 30-day mortality rate. Those with junctional ectopic tachycardia (JET) and restrictive right ventricular physiology have poorer outcomes. Routine postoperative adrenergic or inodilator therapy has been reported, while beta-blockade following cardiopulmonary bypass has not. This study evaluated routine perioperative treatment with esmolol in infants undergoing TOF repair.
Retrospective chart review of the perioperative course following TOF repair.
Single-center case series describing perioperative management of TOF in a cardiac ICU.
This study reviewed all patients less than 18 months old who underwent TOF repair, excluding cases of TOF with absent pulmonary valve or atrioventricular septal defect, at our institution from June 2018 to April 2021.
This review investigates the hemodynamic effects of esmolol following cardiopulmonary bypass for TOF repair.
Preoperative clinical characteristics and perioperative course were extracted from the medical record. Descriptive statistics were used. Twenty-six patients receiving perioperative esmolol after TOF repair were identified and included. Postoperative hemodynamic parameters were within a narrow range with minimal vasoactive support in most patients. Three of 26 patients experienced JET, and one of 26 of whom had a brief cardiac arrest. Median and interquartile range (IQR) for hospital and postoperative length of stay was 7 days (IQR, 6-9 d) and 6 days (IQR, 5-8 d), respectively. There were no 30-day or 1-year mortalities.
In this infant cohort, our experience is that the routine use of postoperative esmolol is associated with good cardiac output with minimal requirement for vasoactive support in most patients. We believe optimal postoperative management of infant TOF repair requires a meticulous multidisciplinary approach, which in our experience is enhanced with routine postoperative esmolol treatment.
目前,法洛四联症(TOF)的手术修复与 1.1%的 30 天死亡率相关。那些患有交界性异位心动过速(JET)和限制性右心室生理的患者预后较差。有报道称常规术后使用肾上腺素能或正性肌力药物治疗,但体外循环后使用β受体阻滞剂尚未报道。本研究评估了 TOF 修复术后常规使用艾司洛尔的围手术期治疗效果。
TOF 修复术后围手术期过程的回顾性图表审查。
单中心病例系列,描述了心脏重症监护病房内 TOF 的围手术期管理。
本研究回顾了我院 2018 年 6 月至 2021 年 4 月期间所有小于 18 个月且行 TOF 修复术的患者,除外法洛四联症伴肺动脉瓣缺如或房室间隔缺损的患者。
本研究调查了 TOF 修复术后体外循环后使用艾司洛尔对血液动力学的影响。
从病历中提取术前临床特征和围手术期过程。使用描述性统计数据。确定并纳入了 26 例接受 TOF 修复术后围手术期艾司洛尔治疗的患者。大多数患者术后血流动力学参数处于较窄范围,仅需少量血管活性药物支持。26 例中有 3 例出现 JET,其中 1 例出现短暂心脏骤停。住院和术后住院时间的中位数和四分位距(IQR)分别为 7 天(IQR,6-9 天)和 6 天(IQR,5-8 天)。无 30 天或 1 年死亡率。
在本婴儿队列中,我们的经验是,术后常规使用艾司洛尔可使大多数患者心输出量良好,仅需少量血管活性药物支持。我们认为,婴儿 TOF 修复的最佳术后管理需要精心的多学科方法,根据我们的经验,常规术后使用艾司洛尔可增强这种方法。